Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement
- 24 February 2014
- journal article
- clinical trial
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 7 (1) , 37-41
Abstract
Objectives: To evaluate the correlation of clinical and urodynamic parameters with bladder vascular resistance before and after dutasteride treatment in patients with lower urinary tract symptoms associated with benign prostatic enlargement.Methods: A prospective study was conducted in 30 consecutive patients with benign prostatic enlargement who had not been satisfied with alpha‐adrenergic antagonist monotherapy. Before and 24 weeks after dutasteride add‐on treatment, we assessed International Prostate Symptom Score (IPSS), prostate volume (PV), urodynamic study and contrast‐enhanced color Doppler ultrasonography to measure bladder vascular resistive index (RI).Results: Twenty‐four weeks after dutasteride, PV significantly decreased from 68 ± 29 to 48 ± 28 mL (P < 0.001), and there was significant improvement of IPSS (from 18.8 ± 7.7 to 13.4 ± 7.2, P < 0.001). Urgency score of IPSS was also significantly improved from 2.3 ± 1.9 to 1.4 ± 1.4 (P < 0.01) after dutasteride. On pressure‐flow study, bladder outlet obstruction index (BOOI) (from 58 ± 36 to 38 ± 27, P < 0.001) and detrusor pressure at Qmax (PdetQmax) (from 73 ± 34 to 54 ± 25 cmH2O, P < 0.001) were significantly improved. RI significantly decreased after dutasteride (from 0.548 ± 0.069 to 0.486 ± 0.064, P < 0.001). In 20 patients with persistent urgency after dutasteride, RI was less improved than in another 10 patients without urgency (change of RI 0.045 ± 0.091 vs. 0.096 ± 0.042, P < 0.05). Post‐treatment BOOI and PdetQmax in patients with persistent urgency was significantly higher than in those without urgency after dutasteride (BOOI: 46 ± 28 vs. 24 ± 20, P < 0.05, PdetQmax: 62 ± 26 vs. 40 ± 17 cmH2O, P < 0.01).Conclusions: Reduction of obstruction and improvement of bladder ischemia might play an important role in a beneficial impact of dutasteride on overactive bladder symptoms.Keywords
This publication has 15 references indexed in Scilit:
- Urodynamic effects of dutasteride add‐on therapy to alpha‐adrenergic antagonist for patients with benign prostatic enlargement: Prospective pressure‐flow studyNeurourology and Urodynamics, 2013
- Analysis of bladder vascular resistance before and after prostatic surgery in patients with lower urinary tract symptoms suggestive of benign prostatic obstructionNeurourology and Urodynamics, 2012
- Effect of the dual 5α‐reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasiaBJU International, 2010
- The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin studyProstate Cancer and Prostatic Diseases, 2009
- Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladderBJU International, 2007
- The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasiaProstate Cancer and Prostatic Diseases, 2006
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- EFFECT OF CHRONIC BLADDER OUTLET OBSTRUCTION ON BLOOD FLOW OF THE RABBIT BLADDERJournal of Urology, 2001
- Reversible Change of Bladder Hypertrophy Due to Benign Prostatic Hyperplasia After Surgical Relief of ObstructionJournal of Urology, 1997
- Blood flow of the urinary bladder: Effects of outlet obstruction and correlation with bioenergetic metabolismNeurourology and Urodynamics, 1995